BioSpace News Archive

IN8bio, Inc. a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, announced the presentation of new preclinical data for its non-signaling gamma-delta T cell based Chimeric Antigen Receptor T cell platform, INB-300.

Tempest Therapeutics, Inc. announced that collaborators at the Beth Israel Deaconess Medical Center at Havard Medical School will present a poster with preclinical data supporting the advancement of TPST-1120 as a potential treatment for renal cell carcinoma at the American Association for Cancer Research Annual Meeting taking place April 5-10, 2024 in San Diego, CA.

Werewolf Therapeutics, Inc. announced the publication of abstracts for upcoming poster presentations at the American Association for Cancer Research Annual Meeting 2024, taking place April 5-10 in San Diego, California.

23andMe Holding Co. announced an oral presentation and two poster presentations on two of the Company’s immuno-oncology programs that will be presented at the American Association for Cancer Research Annual Meeting 2024, taking place in San Diego, CA, April 5-10, 2024.

Lyell Immunopharma, Inc. announced that three abstracts of new nonclinical data have been accepted for presentation at the American Association for Cancer Research Annual Meeting 2024 taking place in San Diego, CA, April 5-10.

RAPT Therapeutics, Inc. announced the acceptance of three late-breaking abstracts for poster presentation, including a poster presentation for tivumecirnon, its lead oncology drug candidate, highlighting phase 2 clinical data in head and neck squamous cell carcinoma, at the American Association for Cancer Research Annual Meeting which will take place April 5-10, 2024 in San Diego, CA.

ALX Oncology Holdings Inc. announced that two clinical abstracts have been accepted for presentation at the American Association for Cancer Research Annual Meeting, which will be held in San Diego from April 5-10, 2024.

C4 Therapeutics, Inc. announced the acceptance of two preclinical poster presentations at the American Association for Cancer Research Annual Meeting 2024 taking place April 5-10, 2024 in San Diego, California.

ORIC Pharmaceuticals, Inc. announced that multiple abstracts have been accepted for presentation, including two oral presentations on ORIC-944, a potent and selective allosteric inhibitor of PRC2, at the 2024 American Association for Cancer Research Annual Meeting taking place April 5-10, 2024, in San Diego, CA.

Merus N.V. announced the publication of an abstract highlighting the preclinical evaluation of the bispecific antibody zenocutuzumab for poster presentation at the American Association for Cancer Research Annual Meeting 2024 taking place in San Diego, CA April 5-10, 2024.